TD Cowen lowered the firm’s price target on Outset Medical (OM) to $12 from $15 and keeps a Buy rating on the shares. The firm said the company’s results met expectations and set appropriate 2026 guidance expectations.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OM:
- Outset Medical price target lowered to $15 from $17 at BTIG
- Outset Medical: Improving Visibility, Stronger Margins, and Next-Gen Tablo Support Buy Rating and $15 Target
- Outset Medical: Stabilizing Execution, Improving Margins, and Balanced 2026 Outlook Support Buy Rating Despite Lower Target
- Outset Medical reports Q4 EPS ($1.09), consensus (68c)
- Outset Medical sees FY26 revenue $125M-$130M, consensus $127.64M